Artikel mit Open-Access-Mandaten - Ricardo Correa-RotterWeitere Informationen
Nicht verfügbar: 2
Effects of Dapagliflozin in Patients Without Diabetes and Microalbuminuria: An Exploratory Analysis From the DAPA-CKD Trial: SA-PO885
HJL Heerspink, G Chertow, N Jongs, R Correa-Rotter, P Rossing, ...
Journal of the American Society of Nephrology 33 (11S), 847-848, 2022
Mandate: US National Institutes of Health
ICU Admission During the COVID-19 Pandemic in Overwhelmed Institutions: Is CKD a Significant Risk Factor for Consideration in ICU Admission?: PUB039
MFZ Miranda, LE Morales-Buenrostro, JM Mejia-Vilet, R Correa-Rotter, ...
Journal of the American Society of Nephrology 32 (10S), 777, 2021
Mandate: US National Institutes of Health
Verfügbar: 48
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
RT Gansevoort, R Correa-Rotter, BR Hemmelgarn, TH Jafar, ...
The Lancet 382 (9889), 339-352, 2013
Mandate: US National Institutes of Health
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis
EVOLVE Trial Investigators
New England Journal of Medicine 367 (26), 2482-2494, 2012
Mandate: US National Institutes of Health
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
A Levin, M Tonelli, J Bonventre, J Coresh, JA Donner, AB Fogo, CS Fox, ...
The Lancet 390 (10105), 1888-1917, 2017
Mandate: US National Institutes of Health
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ...
The Lancet 393 (10184), 1937-1947, 2019
Mandate: US Department of Veterans Affairs
Climate change and the emergent epidemic of CKD from heat stress in rural communities: the case for heat stress nephropathy
J Glaser, J Lemery, B Rajagopalan, HF Diaz, R García-Trabanino, ...
Clinical Journal of the American Society of Nephrology 11 (8), 1472-1483, 2016
Mandate: US Department of Veterans Affairs
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
DC Wheeler, RD Toto, BV Stefansson, N Jongs, GM Chertow, T Greene, ...
Kidney international 100 (1), 215-224, 2021
Mandate: US National Institutes of Health
Fructokinase activity mediates dehydration-induced renal injury
CAR Jimenez, T Ishimoto, MA Lanaspa, CJ Rivard, T Nakagawa, AA Ejaz, ...
Kidney international 86 (2), 294-302, 2014
Mandate: US National Institutes of Health
Dissonant health transition in the states of Mexico, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
H Gómez-Dantés, N Fullman, H Lamadrid-Figueroa, L Cahuana-Hurtado, ...
The Lancet 388 (10058), 2386-2402, 2016
Mandate: Bill & Melinda Gates Foundation
Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes”(KDIGO) Controversies Conference
R Schiffmann, DA Hughes, GE Linthorst, A Ortiz, E Svarstad, DG Warnock, ...
Kidney international 91 (2), 284-293, 2017
Mandate: US National Institutes of Health
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
DC Wheeler, BV Stefansson, M Batiushin, O Bilchenko, DZI Cherney, ...
Nephrology Dialysis Transplantation 35 (10), 1700-1711, 2020
Mandate: US National Institutes of Health
Kidney function in sugarcane cutters in Nicaragua–A longitudinal study of workers at risk of Mesoamerican nephropathy
C Wesseling, A Aragón, M González, I Weiss, J Glaser, NA Bobadilla, ...
Environmental research 147, 125-132, 2016
Mandate: US Department of Veterans Affairs
Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease
JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs, D Postmus, ...
Circulation 143 (5), 438-448, 2021
Mandate: British Heart Foundation
Genetic and environmental risk factors for chronic kidney disease
GT Obrador, UT Schultheiss, M Kretzler, RG Langham, M Nangaku, ...
Kidney international supplements 7 (2), 88-106, 2017
Mandate: Deutsche Forschungsgemeinschaft
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
HJL Heerspink, CD Sjöström, N Jongs, GM Chertow, M Kosiborod, ...
European heart journal 42 (13), 1216-1227, 2021
Mandate: US National Institutes of Health
Effects of dapagliflozin in patients with kidney disease, with and without heart failure
JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs, D Postmus, ...
Heart Failure 9 (11), 807-820, 2021
Mandate: US National Institutes of Health, British Heart Foundation
Hyperosmolarity drives hypertension and CKD—water and salt revisited
RJ Johnson, B Rodriguez-Iturbe, C Roncal-Jimenez, MA Lanaspa, ...
Nature Reviews Nephrology 10 (7), 415-420, 2014
Mandate: US National Institutes of Health
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt …
HJL Heerspink, D Cherney, D Postmus, BV Stefánsson, GM Chertow, ...
Kidney International 101 (1), 174-184, 2022
Mandate: US National Institutes of Health
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy
HJL Heerspink, DL Andress, G Bakris, JJ Brennan, R Correa‐Rotter, ...
Diabetes, Obesity and Metabolism 20 (6), 1369-1376, 2018
Mandate: US National Institutes of Health
Angaben zur Publikation und Finanzierung werden automatisch von einem Computerprogramm ermittelt